Marlene Hart
Psychiatry · Wesley Chapel, FLNPI 1851364046
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 38.9% of the total. Reporting peaked in 2022 at $272 and has fallen 55.1% since, to $122 in 2025.
Across 19 payments — averaging $30.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$229
- E.r. Squibb & Sons, L.L.C.$122
- Johnson & Johnson$92
- Takeda Pharmaceuticals U.S.A., Inc.$48
- Sunovion Pharmaceuticals Inc.$39
- Indivior Inc.$26
- plus $32 from 2 others
Across 83 payments — averaging $4919.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Supernus Pharmaceuticals, Inc.$317K
- Sage Therapeutics, LLC$92K
What the payments were for
- Food & beverage$588100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 7 | $229 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Johnson & Johnson | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Indivior Inc. | 1 | $26 |
| GSK | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$122
How this compares
$588 in reported general payments places this provider in the 55th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 25 | $58,946 |
| TrintellixVortioxetine Hydrobromide | 38 | $25,243 |
| Lurasidone Hcl | 13 | $18,599 |
| Lamotrigine OdtLamotrigine | 12 | $7,647 |
| XanaxAlprazolam | 12 | $7,015 |
| Aripiprazole | 26 | $2,052 |
| Oxcarbazepine | 40 | $1,937 |
| Ziprasidone Hcl | 25 | $1,834 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 31 | $805 |
| Buspirone Hcl | 46 | $728 |
| Mirtazapine | 17 | $608 |
| Topiramate | 54 | $602 |
| Lamotrigine | 19 | $527 |
| Risperidone | 38 | $463 |
| Hydroxyzine Pamoate | 27 | $377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $92 | $58,94625 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $48 | $25,24338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Wesley Chapel
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.